Ubs Group Ag Crispr Therapeutics Ag Call Options Transaction History

Ubs Group Ag

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$44.62 - $62.75 $740,022 - $1.04 Million	-16,585 Reduced 44.95%	20,314 $954,000
Q2 2024 Aug 13, 2024	SELL	$51.17 - $68.18 $111,806 - $148,973	-2,185 Reduced 5.59%	36,899 $1.99 Million
Q1 2024 May 13, 2024	SELL	$60.67 - $89.12 $2.12 Million - $3.11 Million	-34,936 Reduced 47.2%	39,084 $2.66 Million
Q4 2023 Feb 09, 2024	BUY	$38.62 - $72.18 $2.13 Million - $3.99 Million	55,220 Added 293.72%	74,020 $4.63 Million
Q1 2023 May 12, 2023	BUY	$41.0 - $56.12 $770,800 - $1.06 Million	18,800 New	18,800 $850,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.18B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.